Coronavirus, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
Conditions
Keywords
Questionnaire
Brief summary
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the MM and COVID-19 questionnaire.
Interventions
BEHAVIORALQuestionnaire
Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
Sponsors
GlaxoSmithKline
HealthTree Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma. * Access to a computer or electronic device with internet access, or phone * Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma * Willing to give electronically-signed consent * Ability to read questions in English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| COVID-19 Diagnosis and Treatment | Up to one year | Describe how patients diagnosed with COVID-19 were treated for the virus. |
| Changes to Myeloma Treatment and Care | Up to one year | Describe which treatments were changed and how care was affected as a result of COVID-19 |
| Health and Fitness | Up to one year | Describe how COVID-19 impacted patient's health and fitness |
| Quality of Life (QOL) Distress Screening tool | Up to one year | Describe how patients rate their level of concern on psychosocial, practical, and physical needs during the COVID-19 pandemic using the Cancer Support Community's CancerSupportSource distress screening tool. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Trial Familiarity | Upon enrollment | Describe how familiar patients are with multiple myeloma clinical trials. |
Countries
United States
Contacts
Primary ContactNathan Sweeney, PhD
Outcome results
None listed